May 2, 2016, Philadelphia PA. Blackfynn and the Children’s Brain Tumor Tissue Consortium (CBTTC) today announced a partnership focused on improving the way researchers collaborate on complex data generated in the study of pediatric brain tumors.
The CBTTC is a new paradigm for tissue research, not only collecting all types of childhood brain tumors but also performing analysis using cutting-edge technologies and sharing the data with the scientific community at large to develop new treatments. Every year, more than 4,600 children are diagnosed with brain tumors, and despite advances in research and treatment strategies, brain cancer remains the leading cause of cancer-related death in children. The CBTTC, a collaborative of leading children’s hospitals throughout the United States, was created as a way to change this paradigm.
Under the partnership, Blackfynn will provide its data management platform to the CBTTC to enable seamless collaborative science by its members. The partnership will focus on enabling CBTTC members to visualize, annotate, share and search pathology and other relevant research data across the consortium.
“We are thrilled to be working with the CBTTC,” said Amanda Christini, MD, COO of Blackfynn. “Our platform was built specifically to enable collaborative science around complex, multimodal data in the neurosciences in order to accelerate discovery and development of therapeutics. Our partnership with the CBTTC is a great opportunity to work with the leading academic medical centers for pediatric care and research to accelerate the pace of discovery toward effective therapeutics for children’s brain tumors.”
“The Blackfynn platform will enable CBTTC members to share data and discoveries in ways that have not been possible before,” said Adam Resnick, PhD, CBTTC Scientific Chair. “Our partnership with Blackfynn will support thecore goals of the CBTTC to leveraging scientific expertise around data-centric problems that ultimately could lead to improved outcomes for children with brain tumors.”
About Blackfynn Inc.
Blackfynn helps the neuroscience and neurology communities make optimal use of data by powering an innovative platform that integrates and puts complex data in context. The Blackfynn Data Science Platform™ enables seamless upload and visualization of data regardless of source or format, collaborative science across teams, powerful search and links to analytics. Blackfynn’s industry-leading platform enables more effective research and development of personalized medicines, devices and clinical interventions. For more information, please visit www.blackfynn.com.
About the CBTTC
The CBTTC is a collaborative multi-institutional cooperative research program dedicated to the study of childhood brain tumors. The ultimate goal of the CBTTC is to improve outcomes for children with brain tumors by supporting research on new prognostic biomarkers and therapies. The CBTTC has made great strides towards increasing worldwide collaboration and positioning the CBTTC for long term growth and sustainability through integrating informatics advancements, a state of the art biorepository and the leading experts in the field.
The CBTTC consist of 6 primary members and 2 satellite institutions 1) Children’s Hospital of Philadelphia, 2) Seattle Children’s, 3) The Children’s Hospital of Pittsburgh and 4)Ann & Robert H. Lurie Children’s Hospital of Chicago, 5) Benioff Children’s Hospital (UCSF), 6) Stanford University/Lucile Packard Children’s Hospital, 7) Meyer Children’s Hospital Florence Italy and 8) Cancer Institute of New Jersey (Rutgers). Weill Cornell Medical College and Children’s National Medical center have submitted applications for membership to become the 7th and 8th primary member institutions.
The Children’s Hospital of Philadelphia works as the Operations Center, integrating cutting edge genomic and molecular research, a state of the art biorepository and strategic informatics platform creating a foundation to achieve the vision and mission of the CBTTC.
The mission of the CBTTC is to collect high-quality brain tumor biospecimens with associated clinical data, facilitate genomic analysis of biospecimens, develop cell lines and transplantable tumor models from submitted biopsy specimens, and share results from these efforts with CBTTC member institutions and the world-wide scientific community. To achieve this mission, CBTTC shall establish a multi-institutional, collaborative tissue repository and data registry designed to meet the need for high-quality brain tumor biopsy specimens along with relevant, comprehensive clinical data.
The long-term goal of the CBTTC is to actively stimulate tissue-based research and increase worldwide access to the molecular analysis of large numbers of brain tumor specimens by which new childhood brain tumor therapeutic targets can be developed and biologically-based prognostic factors essential to inform therapeutic decisions can be identified.